RS50805B - Upotreba fsh za lečenje neplodnosti - Google Patents

Upotreba fsh za lečenje neplodnosti

Info

Publication number
RS50805B
RS50805B YUP-567/02A YUP56702A RS50805B RS 50805 B RS50805 B RS 50805B YU P56702 A YUP56702 A YU P56702A RS 50805 B RS50805 B RS 50805B
Authority
RS
Serbia
Prior art keywords
fsh
treating infertility
medicament
infertility
women
Prior art date
Application number
YUP-567/02A
Other languages
English (en)
Inventor
Luise DUERR-MYERS
Ernest Loumaye
Original Assignee
Laboratoires Serono Sa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26072975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50805(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP00302840A external-priority patent/EP1142582A1/en
Application filed by Laboratoires Serono Sa. filed Critical Laboratoires Serono Sa.
Publication of YU56702A publication Critical patent/YU56702A/sh
Publication of RS50805B publication Critical patent/RS50805B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Upotreba FSH i/ili nekog njegovog biološki aktivnog analoga u proizvodnji leka za stimulaciju razvoja više folikula u lečenju neplodnosti kod žena, što je naznačeno time da je taj lek za primenu u opsegu doza od 400 do 600 IJ svakog trećeg dana tokom prvih šest dana stimulacione faze.Prijava sadrži još 1 nezavisan i 13 zavisnih patentnih zahteva.
YUP-567/02A 2000-01-27 2001-01-09 Upotreba fsh za lečenje neplodnosti RS50805B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00300591 2000-01-27
EP00302840A EP1142582A1 (en) 2000-04-04 2000-04-04 Use of FSH for treating infertility

Publications (2)

Publication Number Publication Date
YU56702A YU56702A (sh) 2005-09-19
RS50805B true RS50805B (sr) 2010-08-31

Family

ID=26072975

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-567/02A RS50805B (sr) 2000-01-27 2001-01-09 Upotreba fsh za lečenje neplodnosti

Country Status (29)

Country Link
US (1) US7291593B2 (sr)
EP (2) EP1442748A1 (sr)
JP (1) JP5170928B2 (sr)
KR (2) KR100871502B1 (sr)
CN (1) CN1418107A (sr)
AR (1) AR027287A1 (sr)
AT (1) ATE267608T1 (sr)
AU (1) AU783121B2 (sr)
BG (1) BG65915B1 (sr)
BR (1) BR0107881A (sr)
CA (1) CA2397680A1 (sr)
CZ (1) CZ302835B6 (sr)
DE (1) DE60103503T3 (sr)
DK (1) DK1250148T4 (sr)
EA (1) EA004924B1 (sr)
EE (1) EE05444B1 (sr)
ES (1) ES2217113T5 (sr)
HR (1) HRP20020630A2 (sr)
HU (1) HU230833B1 (sr)
IL (2) IL150837A0 (sr)
MX (1) MXPA02007233A (sr)
NO (1) NO324626B1 (sr)
PL (1) PL211113B1 (sr)
PT (1) PT1250148E (sr)
RS (1) RS50805B (sr)
SI (1) SI1250148T2 (sr)
SK (1) SK287717B6 (sr)
TR (1) TR200401810T4 (sr)
WO (1) WO2001054715A1 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501919A (ja) * 2001-09-12 2005-01-20 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 制御下の過排卵刺激におけるｈＣＧ及びＬＨの使用
MEP39208A (en) * 2001-09-12 2011-02-10 Merck Serono Sa USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
US7481748B2 (en) * 2005-09-22 2009-01-27 Kurt Manufacturing Company, Inc. Locking mechanism for a bicycle trainer
EP2150271A1 (en) * 2007-05-11 2010-02-10 The Texas A & M Univsersity System Hormone normalization therapy and uses thereof
AR081755A1 (es) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
WO2015089656A1 (en) * 2013-12-20 2015-06-25 Fertilify Inc. Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health
CN111050787A (zh) * 2017-09-01 2020-04-21 辉凌公司 用于受控的卵巢刺激的组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725579A (en) * 1985-02-21 1988-02-16 Serono Laboratories, Inc. Method of in vitro fertilization by a unique combination of gonadotropins

Also Published As

Publication number Publication date
KR100871499B1 (ko) 2008-12-05
EP1250148B1 (en) 2004-05-26
ES2217113T3 (es) 2004-11-01
AU2532101A (en) 2001-08-07
ATE267608T1 (de) 2004-06-15
HUP0204324A2 (en) 2003-05-28
BR0107881A (pt) 2003-04-01
JP2003520823A (ja) 2003-07-08
BG106943A (bg) 2003-02-28
US20030158106A1 (en) 2003-08-21
US7291593B2 (en) 2007-11-06
EE200200415A (et) 2003-12-15
PL211113B1 (pl) 2012-04-30
NO324626B1 (no) 2007-11-26
KR20070087253A (ko) 2007-08-27
DE60103503D1 (de) 2004-07-01
KR20020081273A (ko) 2002-10-26
NO20023354L (no) 2002-09-24
EA004924B1 (ru) 2004-10-28
CZ302835B6 (cs) 2011-11-30
CA2397680A1 (en) 2001-08-02
CZ20022555A3 (cs) 2002-11-13
AR027287A1 (es) 2003-03-19
EP1250148A1 (en) 2002-10-23
IL150837A0 (en) 2003-02-12
SK287717B6 (en) 2011-07-06
PL356925A1 (en) 2004-07-12
WO2001054715A1 (en) 2001-08-02
HU230833B1 (hu) 2018-07-30
JP5170928B2 (ja) 2013-03-27
HUP0204324A3 (en) 2004-12-28
YU56702A (sh) 2005-09-19
CN1418107A (zh) 2003-05-14
EP1442748A1 (en) 2004-08-04
BG65915B1 (bg) 2010-05-31
PT1250148E (pt) 2004-09-30
MXPA02007233A (es) 2003-02-12
EA200200801A1 (ru) 2003-02-27
DE60103503T3 (de) 2008-12-24
KR100871502B1 (ko) 2008-12-05
HRP20020630A2 (en) 2004-12-31
TR200401810T4 (tr) 2004-09-21
DE60103503T2 (de) 2005-06-09
EP1250148B2 (en) 2008-07-02
ES2217113T5 (es) 2008-11-01
SI1250148T2 (sl) 2008-10-31
SI1250148T1 (en) 2004-08-31
EE05444B1 (et) 2011-08-15
IL150837A (en) 2010-12-30
DK1250148T4 (da) 2008-09-22
DK1250148T3 (da) 2004-08-16
AU783121B2 (en) 2005-09-29
NO20023354D0 (no) 2002-07-11
SK10962002A3 (sk) 2002-12-03

Similar Documents

Publication Publication Date Title
GEP20022786B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and 1kB-a
NO20035743L (no) Substituerte oksazolindinoner for kombinasjonsterapi
HRP20040059B1 (en) Treatment of nail infections with no
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
ATE207342T1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
ES2079414T3 (es) Composiciones para el tratamiento de depositos de grasa en humanos.
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
BR9406893A (pt) Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
EE9900428A (et) Köhavastased ravimkoostised
RS50805B (sr) Upotreba fsh za lečenje neplodnosti
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
HU213677B (en) Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
ES2176495T3 (es) Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida.
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
ATE258375T1 (de) Behandlungen von der foulbroodbienenkrankheit
DK0917460T3 (da) Cyclosporin-formulering
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
ATE493113T1 (de) Topische zubereitung zur behandlung von zehennagelpilz
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
GB9505082D0 (en) Medicament
ATE200026T1 (de) Behandlung von laminitis
PT98764A (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos